July 28, 2020 – Thermo Fisher Scientific Inc. and Lyell Immunopharma, a biotechnology company, are partnering to develop manufacturing processes designed to create more effective cell therapies to benefit cancer patients. The companies will work together to improve the fitness of T cells and Thermo Fisher will support Lyell in its development of an integrated yet flexible cGMP-compliant platform including reagents, consumables and instrumentation.
The intent of the partnership is to gain access and insights into emerging and existing technologies to improve the robustness and consistency of manufacturing operations. This alliance also provides the opportunity for further strategic collaboration in supply chain and commercialization pathways, the company says.
